ClearPoint Neuro, Inc. (CLPT)

NASDAQ: CLPT · IEX Real-Time Price · USD
5.50
-0.01 (-0.18%)
Apr 23, 2024, 4:00 PM EDT - Market closed
-0.18%
Market Cap 148.37M
Revenue (ttm) 23.96M
Net Income (ttm) -22.09M
Shares Out 26.98M
EPS (ttm) -0.90
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 55,009
Open 5.51
Previous Close 5.51
Day's Range 5.43 - 5.63
52-Week Range 4.05 - 10.80
Beta 0.92
Analysts Strong Buy
Price Target 12.00 (+118.18%)
Earnings Date May 9, 2024

About CLPT

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; li... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1998
Employees 107
Stock Exchange NASDAQ
Ticker Symbol CLPT
Full Company Profile

Financial Performance

In 2023, CLPT's revenue was $23.96 million, an increase of 16.56% compared to the previous year's $20.55 million. Losses were -$22.09 million, 34.4% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for CLPT stock is "Strong Buy." The 12-month stock price forecast is $12.0, which is an increase of 118.18% from the latest price.

Price Target
$12.0
(118.18% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations

ClearPoint Neuro platform and SmartFlow Cannula to be used by all centers in AviadoBio's ASPIRE-FTD gene therapy trial treating frontotemporal dementia

7 days ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of ClearPoint Neuro, Inc. (NASDAQ: CLPT)

NEW YORK , April 8, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating ClearPoint Neuro, Inc. (NASDAQ: CLPT) on behalf of the company's shareholders.  The investigation se...

15 days ago - PRNewsWire

ClearPoint Neuro Congratulates its Partner PTC Therapeutics on Completion of Biologics License Application Submission to FDA for Upstaza™ as a Treatment for AADC Deficiency

SOLANA BEACH, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

5 weeks ago - GlobeNewsWire

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2023 Results

SOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

6 weeks ago - GlobeNewsWire

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2023 Results March 12, 2024

SOLANA BEACH, Calif., March 01, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to ...

7 weeks ago - GlobeNewsWire

ClearPoint Neuro Announces Pricing of Public Offering of 2,307,694 Shares of Common Stock

SOLANA BEACH, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

7 weeks ago - GlobeNewsWire

ClearPoint Neuro Launches Proposed Public Offering of Common Stock

SOLANA BEACH, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

7 weeks ago - GlobeNewsWire

ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo

SOLANA BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to t...

3 months ago - GlobeNewsWire

ClearPoint Neuro Announces First EU MDR Certification Success and Approval to Ship Product to Europe

ClearPoint Neuro announces first EU MDR certification success and approval to ship product to Europe from its Carlsbad, California manufacturing facility.

3 months ago - GlobeNewsWire

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...

3 months ago - GlobeNewsWire

ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

SOLANA BEACH, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...

6 months ago - GlobeNewsWire

ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023

SOLANA BEACH, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...

9 months ago - GlobeNewsWire

Top 5 Health Care Stocks That Are Set To Fly In Q2

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BLTECOOIRTCSTAA
11 months ago - Benzinga

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced ...

11 months ago - GlobeNewsWire

ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference

SOLANA BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

1 year ago - GlobeNewsWire

ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles

SOLANA BEACH, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain,...

1 year ago - GlobeNewsWire

ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023

SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brai...

1 year ago - GlobeNewsWire

ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain Model

SOLANA BEACH, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brai...

1 year ago - GlobeNewsWire

ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil

SOLANA BEACH, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brai...

1 year ago - GlobeNewsWire

ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

SOLANA BEACH, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brai...

1 year ago - GlobeNewsWire

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brai...

1 year ago - GlobeNewsWire

ClearPoint Neuro Reports Fourth Quarter and Full-Year 2022 Results

Company Reports Record Revenues Company Reports Record Revenues

1 year ago - GlobeNewsWire

ClearPoint Neuro to Announce Fourth Quarter and Full Year 2022 Revenue Results March 1, 2023

SOLANA BEACH, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...

1 year ago - GlobeNewsWire

ClearPoint Neuro Announces First Patient Enrolled in Glioblastoma Trial Using ClearPoint Prism™ Neuro Laser Therapy System at Skåne University Hospital in Sweden

SOLANA BEACH, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...

1 year ago - GlobeNewsWire

ClearPoint Neuro to Present at Upcoming Investor Conferences

SOLANA BEACH, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain...

1 year ago - GlobeNewsWire